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Abstract
Every year, cancer is responsible for millions of deaths worldwide and, even though 
much progress has been achieved in medicine, there are still many issues that must be 
addressed in order to improve cancer therapy. For this reason, oncological research is 
putting a lot of effort towards finding new and efficient therapies which can alleviate crit-
ical side effects caused by conventional treatments. Different technologies are currently 
under evaluation in clinical trials or have been already introduced into clinical practice. 
While nanomedicine is contributing to the development of biocompatible materials both 
for diagnostic and therapeutic purposes, bioengineering of extracellular vesicles and cells 
derived from patients has allowed designing ad hoc systems and univocal targeting strat-
egies. In this review, we will provide an in-depth analysis of the most innovative advances 
in basic and applied cancer research.
Keywords: cancer, nanomedicine, extracellular vesicles, targeted therapy, immunotherapy, 
gene therapy, thermal ablation, radiomics, pathomics
Introduction
Cancer is one of the main causes of death worldwide, and in the past decade, many 
research studies have focused on finding new therapies to reduce the side effects caused 
by conventional therapies.
During cancer progression, tumours become highly heterogeneous, creating a mixed pop-
ulation of cells characterised by different molecular features and diverse responsivity to 
therapies. This heterogeneity can be appreciated both at spatial and temporal levels and 
is the key factor responsible for the development of resistant phenotypes promoted by a 
selective pressure upon treatment administration [1]. Usually, cancer is treated as a global 
and homogeneous disease and tumours are considered as a whole population of cells. Thus, 
a deep understanding of these complex phenomena is of fundamental importance in order 
to design precise and efficient therapies.
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Nanomedicine offers a versatile platform of biocompatible and biodegradable systems that are able to deliver conventional chemotherapeu-
tic drugs in vivo, increasing their bioavailability and concentration around tumour tissues, and improving their release profile [2]. Nanopar-
ticles can be exploited for different applications, ranging from diagnosis to therapy [2]. 
Recently, extracellular vesicles (EVs), responsible for cancer development, microenvironment modification and required for metastatic pro-
gression, have been widely investigated as efficient drug delivery vehicles [3]. 
Natural antioxidants and many phytochemicals have been recently introduced as anti-cancer adjuvant therapies due to their anti-proliferative 
and pro-apoptotic properties [4, 5].
Targeted therapy is another branch of cancer therapy aiming at targeting a specific site, such as tumour vasculature or intracellular organelles, 
leaving the surroundings unaffected. This enormously increases the specificity of the treatment, reducing its drawbacks [6]. 
Another promising opportunity relies on gene therapy and expression of genes triggering apoptosis [7] and wild type tumour suppressors [8], 
or the targeted silencing mediated by siRNAs, currently under evaluation in many clinical trials worldwide [9].
Thermal ablation of tumours and magnetic hyperthermia are opening new opportunities for precision medicine, making the treatment local-
ised in very narrow and precise areas. These methods could be a potential substitute for more invasive practices, such as surgery [10, 11]. 
Furthermore, new fields such as radiomics and pathomics are contributing to the development of innovative approaches for collecting big 
amounts of data and elaborate new therapeutic strategies [12, 13] and predict accurate responses, clinical outcome and cancer recurrence 
[14–16].
Taken all together, these strategies will be able to provide the best personalised therapies for cancer patients, highlighting the importance of 
combining multiple disciplines to get the best outcome.
In this review, we will provide a general overview of the most advanced basic and applied cancer therapies, as well as newly proposed 
methods that are currently under investigation at the research stage that should overcome the limitation of conventional therapies; differ-
ent approaches to cancer diagnosis and therapy and their current status in the clinical context will be discussed, underlining their impact as 
innovative anti-cancer strategies.
Nanomedicine
Nanoparticles are small systems (1–1,000 nm in size) with peculiar physicochemical properties due to their size and high surface-to-volume 
ratio [17]. Biocompatible nanoparticles are used in cancer medicine to overcome some of the issues related to conventional therapies, such 
as the low specificity and bioavailability of drugs or contrast agents [2]. Therefore, encapsulation of the active agents in nanoparticles will 
increase their solubility/biocompatibility, their stability in bodily fluids and retention time in the tumour vasculature [18–20]. Furthermore, 
nanoparticles can be engineered to be extremely selective for a precise target [21, 22] (see the “Targeted therapy and immunotherapy” 
section) and to release the drug in a controlled way by responding to a specific stimulus [18, 23–25]. This is the case of ThermoDox, a 
liposomal formulation that can release doxorubicin as a response to an increment of temperature [26].
Inorganic nanoparticles are generally used as contrast agents for diagnosis purposes. Among them, quantum dots are small light-emitting 
semiconductor nanocrystals with peculiar electronic and optical properties, which make them highly fluorescent, resistant to photobleaching 
and sensitive for detection and imaging purposes [27]. Combined with active ingredients, they can be promising tools for theranostic applica-
tions [27]. In a recent study, quantum dots coated with poly(ethylene glycol) (PEG) were conjugated to anti-HER2 antibody and localised in 
specific tumour cells [28].
Superparamagnetic iron oxide nanoparticles (SPIONs) are usually exploited as contrast agents in magnetic resonance imaging (MRI) because 
they interact with magnetic fields [29, 30]. Five types of SPIONs have been tested for MRI: ferumoxides (Feridex in the US, Endorem in 
Europe), ferucarbotran (Resovist), ferucarbotran C (Supravist, SHU 555 C), ferumoxtran-10 (Combidex) and NC100150 (Clariscan). Ferucar-
botran is currently available in few countries, while the others have been removed from the market [25]. SPIONs have also been studied for 
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cancer treatment by magnetic hyperthermia (see the “Thermal ablation and magnetic hyperthermia” section), and a formulation of iron oxide 
coated with aminosilane called Nanotherm has been already approved for the treatment of glioblastoma [31].
Gold nanoparticles have raised interest because of their optical and electrical properties and low toxicity [32–34]. They are mainly used as 
contrast agents for X-ray imaging, computed tomography [25], photoacoustic imaging [35] and photodynamic therapy [36]. A nanoshell made 
of a silica core and a gold shell coated with PEG was approved by the Food and Drug Administration (FDA) in 2012 and commercialised as 
AuroShell (Nanospectra) for the treatment of breast cancer by photodynamic therapy [25].
Organic nanoparticles are mainly used as delivery systems for drugs. Liposomes and micelles are both made of phospholipids, but they differ 
in their morphology. Liposomes are spherical particles having at least one lipid bilayer, resembling the structure of cell membranes. They 
are mainly used to encapsulate hydrophilic drugs in their aqueous core, but hydrophobic drugs can also be accommodated in the bilayer 
or chemically attached to the particles [37]. Micelles, instead, own a hydrophobic core that can encapsulate hydrophobic drugs [38]. Doxil, 
doxorubicin-loaded PEGylated liposomes, were the first nanoparticles approved by the FDA in 1995 to treat AIDS-associated Kaposi’s 
sarcoma [39]. This formulation drastically reduces doxorubicin side effects. Since then, other liposomal formulations have been approved 
by the FDA for cancer therapy, such as Myocet and DaunoXome [40–42]. Polymeric nanoparticles are made of biocompatible or natural 
polymers, such as poly(lactide-co-glycolide), poly(ε-caprolactone), chitosan, alginate and albumin [43]. Some formulations have already been 
accepted by the FDA, such as Abraxane (albumin-paclitaxel particles for the treatment of metastatic breast cancer and pancreatic ductal ade-
nocarcinoma) and Ontak (an engineered protein combining interleukin-2 and diphtheria toxins for the treatment of non-Hodgkin’s peripheral 
T-cell lymphomas).
As well as these systems, which have been either accepted or are under clinical investigation, it is worth mentioning some new nanoparticles 
currently undergoing testing at the research level, which should improve treatment performance. For example, solid lipid nanoparticles, made 
of lipids that are solid at body temperature [44], and fabricated to load hydrophobic drugs [45] have been demonstrated to give a higher drug 
stability and prolonged release compared to other systems; however, the encapsulation efficiency is often low because of their high crystal-
linity [46]. To overcome this issue, one or more lipids, liquid at room temperature (like oleic acid, for example), are included in the formulation 
[47]. Lipid nanoparticles are good candidates for brain tumour therapy as they are able to cross the blood–brain barrier (BBB) [48]. A recent 
work showed that lipid nanoparticles loaded with SPIONs and temozolomide are efficient to treat glioblastoma since they combine the effect 
of the conventional chemotherapy and hyperthermia [49, 50]. Dendrimers are another family of nanoparticles composed of polymers with a 
repetitive branched structure and characterised by a globular morphology [51, 52]. Their architecture can be easily controlled, making their 
structure extremely versatile for many applications. For example, some recent studies show that poly-L-lysine (PLL) dendrimers loaded with 
doxorubicin induce anti-angiogenic responses in in vivo tumour models [53]. Currently, there is only one clinical trial for a formulation named 
ImDendrim based on a dendrimer and on a rhenium complex coupled to an imidazolium ligand, for the treatment of inoperable liver cancers 
that do not respond to conventional therapies [54].
Extracellular vesicles for cancer diagnosis and therapy
EVs are classified in two categories based on their biogenesis. Specifically, exosomes are small vesicles of around 30–150 nm originated 
from endosomes in physiological and pathological conditions and released by a fusion of multivesicular bodies (MVBs) to the cell membrane 
[55, 56], while shed microvesicles (sMVs), with a typical size of 50–1,300 nm, are present in almost any extracellular bodily fluid and are 
responsible for the exchange of molecular materials between cells [57, 58]. Exosomes are involved in cancer development and spreading 
[3, 59, 60], in the bidirectional communication between tumour cells and surrounding tissues, and in the construction of the microenviron-
ment needed for pre-metastatic niche establishment and metastatic progression [61]. Hence, circulating vesicles are clinically relevant in 
cancer diagnosis, prognosis and follow up. Exosomes are actually recognised as valid diagnostic tools, but they can also be isolated and 
exploited as anti-cancer vaccines or nanosized drug carriers in cancer therapy [62].
Nowadays, one of the main issues in cancer diagnosis is the early identification of biomarkers by non-invasive techniques. Obtaining a sig-
nificant amount of information, before and during tumour treatment, should allow the monitoring of cancer progression and the efficacy 
of therapeutic regimens. Liquid biopsies to detect circulating tumour cells, RNAs, DNAs and exosomes have been used as indicators for 
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personalised medicine [63]. In recent years, exosomes detection has been validated as a reliable tool for preclinical practice in different 
cancer types [64], thanks to the identification of their content: double-stranded DNA (dsDNA) [65, 66], messenger RNA (mRNA), micro 
RNA (miRNA), long non-coding RNA (lncRNA) [67], proteins and lipids [68]. DsDNA has been detected in exosomes isolated from plasma 
and serum of different cancer cell types, and mutated genes involved in tumorigenesis, such as mutated KRAS and TP53 [69, 70], have been 
identified as disease predictors. Similarly, exosomal AR-V7 mRNA has been used as a prognostic marker of resistance to hormonal therapy in 
metastatic prostate cancer patients [71]. Gene expression profiling of multiple RNAs from urinary exosomes has been adopted as an efficient 
diagnostic tool [72]. LncRNAs isolated from serum exosomes have been exploited for disease prognosis in colorectal cancer patients [73], 
and multiple miRNAs allow one to distinguish between different lung cancer subtypes [74]. GPC1-positive exosomes have been employed 
to detect pancreatic cancer [75], while circulating exosomal macrophage migration inhibitory factor (MIF) was able to predict liver metastasis 
onset [76]. Finally, multiple lipids present in urinary exosomes have been approved as prostate cancer indicators [77]. Due to the high vari-
ability of patient classes and sample size, and in order to obtain clinically significant results for a fast and effective diagnosis, huge invest-
ments in exosome research will be required in the near future.
Exosomes could also be exploited as natural, biocompatible and low immunogenic nanocarriers for drug delivery in cancer therapy. They 
can be passively loaded by mixing purified vesicles with small drugs [78–82], or actively loaded by means of laboratory techniques, such as 
electroporation and sonication [83, 84]. Superparamagnetic nanoparticles conjugated to transferrin have been tested for the isolation of 
exosomes expressing transferrin receptor from mice blood. After incubation with doxorubicin, they have been used to target liver cancer cells 
in response to external magnetic fields, inhibiting cell growth both in vitro and in vivo [80]. Kim et al. [83] engineered mouse macrophage-
derived exosomes with aminoethyl anisamide-PEG to target sigma receptor, overexpressed in lung cancer cells and passively loaded them 
with paclitaxel. These systems acted as targeting agents able to suppress metastatic growth in vivo.
Three clinical trials with loaded exosomes are currently ongoing for the treatment of different tumours [85–87]: a phase I trial is evaluating 
the ability of exosomes to deliver curcumin to normal and colon cancer tissues [85]; a phase II trial is investigating the in vivo performance of 
autologous tumour cell-derived microparticles carrying methotrexate in lung cancer patients [86] and a clinical inquiry is focusing on autolo-
gous erythrocyte-derived microparticles loaded with methotrexate for gastric, colorectal and ovarian cancer treatment [87].
Recently, new strategies to produce ad hoc exosomes have been developed. Cells releasing exosomes have been genetically engineered to 
overexpress specific macromolecules, or modified to release exosomes with particular targeting molecules [88–90].
Exosomes derived from different cancer cells have already been exploited as cancer vaccines. Autologous dendritic cell-derived exosomes 
with improved immunostimulatory function have been tested in a phase II clinical trial for the activation of CD8+ T cells [91] in non-small cell 
lung cancer (NSCLC) patients, observing disease stabilisation and a better overall survival [92]. In a phase I trial, ascites-derived exosomes 
supplemented with granulocyte-macrophage colony stimulating factor (GM-CSF) have been administered to colorectal cancer patients, solic-
iting a tumour-specific immune response [93].
Many issues related to exosomes clinical translation remain open and are mostly connected to the definition of preclinical procedures for 
isolation, quantification, storage and standard protocols for drug loading. It is becoming even more necessary to distinguish between tumour 
and healthy blood cell-derived vesicles to characterise their post-isolation half-life and to perform standard content analyses. For these pur-
poses, innovative approaches and technologies have been set up, such as microarrays and specific monoclonal antibodies and RNA markers 
amplification strategies [94].
Natural antioxidants in cancer therapy
Every day, the human body undergoes several exogenous insults, such as ultraviolet (UV) rays, air pollution and tobacco smoke, which result 
in the production of reactive species, especially oxidants and free radicals, responsible for the onset of many diseases, including cancer. These 
molecules can also be produced as a consequence of clinical administration of drugs, but they are also naturally created inside our cells and 
tissues by mitochondria and peroxisomes, and from macrophages metabolism, during normal physiological aerobic processes.
Oxidative stress and radical oxygen species are able to damage DNA (genetic alterations, DNA double strand breaks and chromosomal aber-
rations [95, 96]) and other bio-macromolecules [97], such as lipids (membrane peroxidation and necrosis [98]) and proteins (significantly 
changing the regulation of transcription factors and, as a consequence, of essential metabolic pathways [99]).
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The protective mechanisms our body has developed against these molecules are sometimes insufficient to counteract the huge damages 
produced. Recently, in addition to research into the roles of the physiological enzymes superoxide dismutase (SOD), catalase (CAT) and gluta-
thione peroxidase (GP), natural antioxidants such as vitamins, polyphenols and plant-derived bioactive compounds are being studied in order 
to introduce them as preventive agents and potential therapeutic drugs [100, 101]. These molecules have anti-inflammatory and anti-oxidant 
properties and are found in many vegetables and spices [102]. Vitamins, alkaloids, flavonoids, carotenoids, curcumin, berberine, quercetin 
and many other compounds have been screened in vitro and tested in vivo, displaying appreciable anti-proliferative and pro-apoptotic proper-
ties, and have been introduced as complementary therapies for cancer [4, 5, 103].
Despite the advantages of using natural drugs, their translation into clinical practice remains difficult due to their limited bioavailability and/
or toxicity. Curcumin, a polyphenolic compound extracted from turmeric (Curcuma longa), is a traditional Southeast Asian remedy with anti-
inflammatory, anti-oxidant and chemopreventive and therapeutic activities [104]. It has been shown to have cytotoxic effects in different 
kinds of tumours, such as brain, lung, leukaemia, pancreatic and hepatocellular carcinoma [105, 106], with no adverse effects in normal 
cells at the effective therapeutic doses [107]. Curcumin can modulate a plethora of cellular mechanisms [108, 109]; however, its biological 
properties, and as a consequence, the treatment duration and the efficient therapeutic doses, have not been completely elucidated yet. This 
molecule is highly lipophilic, poorly soluble in water and not very stable [110]. Different strategies and specific carriers, such as liposomes 
and micelles [111, 112], have been developed to improve its bioavailability. Currently, 24 clinical trials involving curcumin are ongoing and 
23 have been already completed [113].
Berberine is an alkaloid compound extracted from different plants, such as Berberis. Recently, it has been demonstrated to be effective 
against different tumours and to act as a chemopreventive agent, modulating many signalling pathways [114, 115]. Like curcumin, it is poorly 
soluble in water; therefore, different nanotechnological strategies have been developed to facilitate its delivery across cell membranes 
[116–119]; six clinical trials are open and one has been completed [120].
Quercetin, a polyphenolic flavonoid found in fruits and vegetable, has been proven to be effective to treat several tumours, such as lung, 
prostate, liver, colon and breast cancers [121–123], by binding cellular receptors and interfering with many signalling pathways [124]. Inter-
estingly, it has been shown to be effective also in combination with chemotherapeutic agents [125]. Presently, seven clinical trials are open 
and four have been completed [126].
Targeted therapy and immunotherapy
One of the main problems of conventional cancer therapy is the low specificity of chemotherapeutic drugs for cancer cells. In fact, most drugs 
act both on healthy and diseased tissues, generating severe side effects. Researchers are putting a lot of effort into finding a way to target 
only the desired site. Nanoparticles have raised great interest for their tendency to accumulate more in tumour tissues due to the enhanced 
permeability and retention effect (EPR) [127]. This process, called passive targeting, relies on the small size of nanoparticles and the leaky 
vasculature and impaired lymphatic drainage of neoplastic tissues [6]. Passive targeting, however, is difficult to control and can induce mul-
tidrug resistance (MDR) [128]. Active targeting, on the other hand, enhances the uptake by tumour cells by targeting specific receptors that 
are overexpressed on them [129, 130]. Nanoparticles, for example, can be functionalized with ligands that univocally bind particular cells or 
subcellular sites [6]. Several kinds of ligands can be used, such as small molecules, peptides, proteins, aptamers and antibodies.
Folic acid and biotin are small molecules, whose receptors are overexpressed in tumour tissues. Several nanocarriers have been functional-
ized with folic acid to target ovarian and endometrial cancers [131]: folic acid-conjugated polyethylene glycol-poly(lactic-co-glycolic acid) 
nanoparticles delivering docetaxel increased drug cellular uptake by human cervical carcinoma cells [132]. Small ligands are cheap and can 
be linked to nanoparticles by simple conjugation chemistry [133, 134].
Different kinds of small peptides and proteins are also effective in active targeting. Angiopep-2 is a peptide that has raised great interest in the 
treatment of brain cancer [135], because it binds to low-density lipoprotein receptor-related protein-1 (LRP1) of endothelial cells in the BBB, 
and it is also overexpressed in glioblastoma cancer cells [136]. Bombesin peptide conjugated to poly(lactic-co-glycolic acid) (PLGA) nanopar-
ticles loaded with docetaxel was used to target the gastrin-releasing peptide receptor, overexpressed on cell surface of prostate, breast, ovar-
ian, pancreatic and colorectal cancer cells [137, 138]. Transferrin is a serum glycoprotein overexpressed on many solid tumours, especially on 
glioblastoma multiforme cells [139], and on epithelial cells of the BBB [6, 140]. Transferrin-conjugated chitosan-PEG nanoparticles delivering 
paclitaxel exhibited a higher cytotoxicity towards transferrin-overexpressing human non-small cell lung cancer cells (NSCLCs) (HOP-62) [141].
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Aptamers are small synthetic single-stranded RNA or DNA oligonucleotides folded into specific shapes that make them capable of binding 
specific targets [142]. Farokhzad et al. [143] reported that the use of A10 RNA aptamer conjugated to docetaxel-loaded nanoparticles signifi-
cantly enhances in vitro cytotoxicity. The same aptamer has been also used to prepare quantum dot-doxorubicin conjugates [144].
Antibodies are currently the most exploited ligands for active targeting. These proteins have a typical ‘Y’ shape, where the two arms are 
responsible for the selective interaction with the antigen [145]. Antibodies can be used as immunoconjugates, when conjugated to a drug or 
nanoparticle, or naked. In the first case, their function is mainly to target a specific antigen overexpressed on cancer cells. Antibodies used 
for this purpose include those ones that bind to the human epidermal growth factor receptor 2 (HER2), the epidermal growth factor recep-
tor (EGFR), the transferrin receptor (TfR) and the prostate-specific membrane antigen (PSMA) [6]. Rapamycin-PLGA nanoparticle conjugated 
to EGFR antibody exhibited higher cellular uptake by human breast adenocarcinoma cells (MCF-7), with enhanced apoptotic activity [146]. 
Loperamide-loaded human serum albumin nanoparticles conjugated to antibodies that specifically bind transferrin receptor successfully 
crossed the BBB and delivered the drug to the desired site [147].
Naked antibodies or immunoconjugates can also be used in immunotherapy, which is a cancer treatment that aims at stimulating or restoring 
the immune system of the patient against cancer cells [148]. Antibodies can act as markers for cancer cells to make them more vulnerable 
to the immune system response (non-specific immune stimulation), or as inhibitors for immune checkpoint proteins on cancer cell surface, 
that can modulate the action of T-cells [148]. Several antibodies have been already tested and accepted by FDA for immunotherapy, such 
as rituximab (1997, [149]), ibritumomab tiuxetan (2002, [150]), trastuzumab emtansine (2013, [151]), nivolumab (2014, [152]) and pembro-
lizumab (2014, [153]). 
Immunotherapy can be achieved by another strategy called adoptive cell transfer (ACT) and it consists of isolating T-lymphocytes (T-cells) 
with the highest activity against cancer directly from the patient’s blood, expanding them ex vivo, and reinfusing them again into the patient 
[154]. Autologous T-cells can be genetically engineered in vitro to express a chimaeric antigen receptor (CAR), which makes them more spe-
cific against cancer cell antigens [148]. Different CARs can be designed to be directed against a certain cancer antigen. The genetic modifica-
tion of T-cells can be achieved by different methods such as viral transduction, non-viral methods like DNA-based transposons, CRISPR/Cas9 
or other plasmid DNA and mRNA transfer techniques (i.e., electroporation, encapsulation in nanoparticles) [155]. ACT protocols have been 
already adopted in clinical practice for advanced or recurrent acute lymphoblastic leukaemia and for some aggressive forms of non-Hodgkin’s 
lymphoma [148]. For example, it has been shown that the treatment of end-stage patients affected by acute lymphocytic leukaemia with 
CAR T-cells led to a full recovery in up to 92% of patients [155]. Despite these very promising results, much research is currently devoted 
to understanding the long-term side effects of CAR T-cell therapies and their fate within tumours, and to improving CAR T-cell expansion 
technologies.
Gene therapy for cancer treatment
Gene therapy is intended as the introduction of a normal copy of a defective gene in the genome in order to cure specific diseases [156]. 
The first application dates back to 1990 when a retroviral vector was exploited to deliver the adenosine deaminase (ADA) gene to T-cells in 
patients with severe combined immunodeficiency (SCID) [157]. Further research demonstrated that gene therapy could be applied in many 
human rare and chronic disorders and, most importantly, in cancer treatment. Approximately 2,900 gene therapy clinical trials are currently 
ongoing, 66.6% of which are related to cancer [158]. Different strategies are under evaluation for cancer gene therapy: 1) expression of pro-
apoptotic [159, 160] and chemo-sensitising genes [4]; 2) expression of wild type tumour suppressor genes [5]; 3) expression of genes able to 
solicit specific antitumour immune responses and 4) targeted silencing of oncogenes.
One approach relied on thymidine kinase (TK) gene delivery, followed by administration of prodrug ganciclovir to activate its expression and 
induce specific cytotoxicity [161]. This has been clinically translated for the treatment of prostate cancer and glioma [162–164]. In recent 
decades, different vectors carrying the p53 tumour suppressor gene have been evaluated for clinical applications. ONYX-015 has been 
tested in NSCLC patients and gave a high response rate when administered alone or together with chemotherapy [165]. Gendicine, a recom-
binant adenovirus carrying wild-type p53 in head and neck squamous cell cancer had a similar success, inducing complete disease regression 
when combined with radiotherapy [166].
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Despite many achievements, there are still some challenges to face when dealing with gene therapy, such as the selection of the right condi-
tions for optimal expression levels and the choice of the best delivery system to univocally target cancer cells. Gene therapy also presents 
some drawbacks linked to genome integration, limited efficacy in specific subsets of patients and high chances of being neutralised by the 
immune system. Therefore, particular interest has been elicited by targeted gene silencing approaches. 
RNA interference (RNAi) has been recently established as an efficient technology both for basic research and medical translation. Small inter-
fering RNAs (siRNAs) consist of double-stranded RNAs [167] able to produce targeted gene silencing. This process is intracellularly medi-
ated by the RNA-induced silencing complex (RISC), responsible for cleaving the messenger RNA (mRNA), thus leading to interference with 
protein synthesis [168]. This physiological mechanism has been demonstrated in many eukaryotes, including animals. A few years after RNAi 
discovery, the first clinical application for wet-age related macular degeneration treatment entered phase I clinical trial [169]. Since cancer is 
triggered by precise molecular mechanisms, siRNAs can be rationally designed to block desired targets responsible for cell proliferation and 
metastatic invasion. This strategy relies on siRNA-mediated gene silencing of anti-apoptotic proteins [170], transcription factors (i.e., c-myc 
gene) [171, 172] or cancer mutated genes (i.e., K-RAS) [173]. Most of the clinical trials currently ongoing are based on local administration 
of siRNA oligonucleotides in a specific tissue/organ or on systemic delivery throughout the entire body [9, 174]. Using siRNA-based drugs 
has several advantages: 1) safety, since they do not interact with the genome; 2) high efficacy, because only small amounts can produce a 
dramatic gene downregulation; 3) possibility of being designed for any specific target; 4) fewer side effects when compared to conventional 
therapies and 5) low costs of production [175, 176]. However, siRNAs are relatively unstable in vivo and can be phagocytosed during blood 
circulation, excreted by renal filtration, or undergo enzymatic degradation [177]. Occasionally, they can induce off-target effects [178] 
or elicit innate immune responses, followed by specific inflammation [179, 180]. Since naked siRNAs are negatively charged hydrophilic 
molecules, they cannot spontaneously cross cell membranes. Consequently, different delivery strategies are currently under study, such as 
chemical modification, encapsulation into lipid or polymeric carriers or conjugation with organic molecules (polymers, peptides, lipids, anti-
bodies, small molecules [181], for efficient targeting [182, 183]). Chemical modifications include the insertion of a phosphorothioate at 3’ end 
to reduce exonuclease degradation [184], the introduction of 2’ O-methyl group to obtain longer half-life in plasma [185] and the modifica-
tion by 2,4-dinitrophenol to favour membrane permeability [186]. Nevertheless, the degradation of modified siRNAs often elicits cytotoxic 
effects; therefore, it is preferable to design ad hoc nanocarriers.
Different cationic lipid nanoparticles, such as liposomes, micelles and solid lipid nanoparticles [183], have been exploited for siRNA load-
ing. Cationic liposomes interact with negatively charged nucleic acids, which can be easily transfected by simple electrostatic interactions 
[187, 188]. They can be constituted by 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and N-{1-(2,3-dioleoyloxy) propyl]-N,N,N-
trimethylammonium methyl sulphate (DOTMA) [189]. A theranostic agent consisting of an anticancer survivin siRNA entrapped in PEGylated 
liposomes has been developed to achieve simultaneous localisation inside tumour cells by means of entrapped MR agents and fluorophores 
and reduction of proliferation in vivo [190].
Neutral liposomes based on 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) have shown high efficacy in mice models of ovarian 
carcinoma and colorectal cancer [191, 192]. A phase I clinical trial is currently recruiting patients for evaluating the safety of siRNA-EphA2-
DOPC when administered to patients with advanced and recurrent cancer [193].
Stable nucleic acid lipid particles (SNALPs) have been evaluated in non-human primates [194]. SiRNAs have been encapsulated in a mix-
ture of cationic lipids coated with a shell of polyethylene glycol (PEG) [195]. SNALPs entered a phase I clinical trial in patients affected by 
advanced solid tumours with liver involvement [196] and a phase I/II trial for treating neuroendocrine tumours and adrenocortical carcinoma 
patients refractory to standard therapy [197].
SiRNAs can be condensed in cationic polymers such as chitosan, cyclodextrin and polyethylenimine (PEI). Chitosan is a natural polysac-
charide that, due to its cationic charge, has been exploited as carrier for nucleic acids in vitro and in vivo [198]. Specifically, a targeted siRNA 
has been delivered in mice xenografts of breast cancer [199]. Cyclodextrin polymers coated with PEG, conjugated with human transferrin 
and carrying a siRNA called CALAA-01, inhibit tumour growth by reducing the expression of M2 subunit of ribonucleotide reductase (R2), 
and have entered a phase I clinical trial [200]. PEI is able to form small cationic nanoparticles containing siRNAs and it has been exploited as 
antitumoural, upon loading with HER-2 receptor-specific siRNA [201]. A phase II clinical trial is presently starting to evaluate siG12D LODER 
directed to mutated KRAS oncogene and encapsulated into a biodegradable polymeric matrix for locally treating advanced pancreatic cancer 
patients in combination with chemotherapy [202].
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SiRNAs may be conjugated to peptides, antibodies and aptamers in order to improve their stability during circulation and to enhance cellular 
uptake [203]. A success is represented by siRNAs targeting PSMA, overexpressed in this type of cancer [204].
The introduction of nanocarriers has largely improved siRNAs stability, pharmacokinetics and biodistribution properties, and the targeting speci-
ficity [205, 206]. Smart nanomaterials responsive to external (i.e., magnetic field, ultrasounds) and tumour-specific stimuli (i.e., acidic pH, redox 
conditions) are currently under the development for controlled release and reduction of undesired negative effects [207, 208]. Nanocarriers 
delivering siRNAs undergo a series of pH variations from blood circulation to intracellular environment and, for this reason, many pH responsive 
materials have been designed to favour cargo release under specific pH conditions [209]. Poly(allylamine) phosphate nanocarriers, stable at 
physiological pH, have been developed to release siRNAs in the cytoplasm after disassembly at low endosomal pH [210].
Although there have been many successes, some questions remain open and make the clinical translation of the siRNA-based approach 
very challenging, such as the correct doses to be delivered to patients and the many variabilities observed between individuals and different 
stages of disease. Further research towards controlled release to reach only specific targets, and the set-up of the best personalised therapy 
for cancer patients will be necessary in the near future.
Thermal ablation and magnetic hyperthermia
Thermal ablation of tumours includes a series of techniques that exploit heat (hyperthermia) or cold (hypothermia) to destroy neoplastic 
tissues [13]. It is known that cell necrosis occurs at temperatures lower than -40°C or higher than 60°C. Long exposures to temperatures 
between 41°C and 55°C are also effective for tumour cell damage. Moreover, it has been shown that cancer cells are more sensitive to high 
temperatures than healthy ones [211].
Hypothermic ablation is due to the formation of ice crystals upon cooling, which destroy cell membranes and finally kill cells. Argon gas is the 
preferred cooling agent because it can cool down the surrounding tissues to -160°C. Also, gases at their critical point, such as nitrogen, can 
be exploited since they have a higher heat capacity than argon. However, the technology to control and direct them is not well developed 
yet [10]. 
Hyperthermic ablation currently comprises radiofrequency (RF), microwave and laser ablation [10]. 
RF ablation is the most used in clinics, because it is effective and safe [212]. An alternated current of RF waves is applied to a target zone 
by an insulated electrode tip, while a second electrode, needed to close the circuit, is placed on the skin surface [10]. The interaction with 
the current causes the oscillation of ions in the extracellular fluid, which, in turns, produces heat. The more conductive the medium, the 
more effective the process. For this reason, RF ablation works very well in the liver and in other areas with a high content of water and ions, 
whereas it has a poor effect in lungs [10]. Moreover, the efficiency of the treatment decreases with the size of the lesion, giving the best 
results for areas not larger than 3 cm2 [213, 214].
Microwave ablation is based on the electromagnetic interaction between microwaves and the polar molecules in tissues, like water, that 
causes their oscillation and the consequent increase in temperature. Unlike the electrical current in RF ablation, microwaves can propagate 
through any kind of tissue [215, 216], and this allows high temperatures to be reached in a short amount of time, to have a deeper penetra-
tion and to treat larger areas of tumours [217]. 
Laser therapy exploits the properties of laser beams of being very narrow and extremely focused at a specific wavelength. This makes the 
treatment very powerful and precise, thus a promising alternative to conventional surgery [218]. The absorption of the light emitted by the 
laser results in the heating and subsequent damage of the treated area [219]. Depending on the specific application, different kinds of lasers 
can be used. Neodymium:yttrium-aluminium-garnet (Nd:YAG) lasers (wavelength of 1064 nm) and diode lasers (wavelength of 800–900 nm) 
are used to treat internal organs, since they have a penetration depth up to 10 cm [218]. Conversely, CO2 lasers (10,600 nm), with a penetra-
tion depth of 10 μm up to 1 mm maximum are used for superficial treatments. Laser therapy is receiving a lot of attention in research because 
of its advantages compared to other ablation techniques, such as a higher efficacy, safety and precision, and a shorter treatment session 
needed to achieve the same results [220, 221]. Moreover, the fibres to transmit laser light are compatible with MRI, allowing for a precise 
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measure of the temperature and the thermal dose [222]. However, there are still some limitations to overcome, such as the need of a very 
skilled operator to place the fibre in the correct position [218]. 
Finally, a new way to heat tumour tissues, currently under study, is through magnetic hyperthermia. This technique exploits superparamag-
netic or ferromagnetic nanoparticles that can generate heat after stimulation with an alternating magnetic field. The most studied systems in 
nanomedicine are SPIONs [11]. The production of heat, in this case, is due to the alignment of magnetic domains in the particles when the 
magnetic field is applied, and the subsequent relaxation processes (Brownian and/or Neel relaxations) during which heat is released, when 
the magnetic field is removed and the magnetisation of the particles reverts to zero [223]. Magnetic hyperthermia can reach any area of the 
body and SPIONs can also act as MRI contrast agents to follow their correct localisation before the stimulation. The particles can be coated 
with biocompatible polymers and/or lipid and functionalized with specific ligands to impart targeting properties [224]. As already mentioned, 
until now, just a formulation of 15-nm iron oxide nanoparticles coated with aminosilane (Nanotherm) obtained approval for the treatment of 
glioblastoma [31]. SPIONs have also been successfully encapsulated in lipid nanocarriers together with a chemotherapeutic agent to combine 
chemotherapy and hyperthermia [49, 50].
Recent innovations in cancer therapy: Radiomics and pathomics
Efficient cancer therapy currently relies on surgery and, in approximately 50% of patients, on radiotherapy, that can be delivered by using an 
external beam source or by inserting locally a radioactive source (in this case, the approach is named brachytherapy), thus obtaining focused 
irradiation. Currently, localisation of the beam is facilitated by image-guided radiotherapy (IGRT), where images of the patient are acquired 
during the treatment allowing the best amount of radiation to be set. Thanks to the introduction of intensity-modulated radiotherapy (IMRT), 
radiation fields of different intensities can be created, helping to reduce doses received by healthy tissues and thus limiting adverse side 
effects. Finally, by means of stereotactic ablative radiotherapy (SABR), it has become feasible to convey an ablative dose of radiation only to 
a small target volume, significantly reducing undesired toxicity [225].
Unfortunately, radioresistance can arise during treatment, lowering its efficacy. This has been linked to mitochondrial defects; thus, targeting 
specific functions have proven to be helpful in restoring anti-cancer effects [226]. A recent study has shown, for example, that radioresistance 
in an oesophageal adenocarcinoma model is linked to an abnormal structure and size of mitochondria, and the measurement of the energy 
metabolism in patients has allowed discrimination between treatment resistant and sensitive patients [227]. Targeting mitochondria with 
small molecules acting as radiosensitizers is being investigated for gastrointestinal cancer therapy [228].
Cancer is a complex disease and its successful treatment requires huge efforts in order to merge the plethora of information acquired during 
diagnostic and therapeutic procedures. The ability to link the data collected from medical images and molecular investigations has allowed an 
overview to be obtained of the whole tridimensional volume of the tumour by non-invasive imaging techniques. This matches with the main aim of 
precision medicine, which is to minimise therapy-related side effects, while optimising its efficacy to achieve the best individualised therapy [229]. 
Radiomics and pathomics are two promising and innovative fields based on accumulating quantitative image features from radiology and 
pathology screenings as therapeutic and prognostic indicators of disease outcome [12, 13, 230]. Many artificial intelligence technologies, 
such as machine learning application, have been introduced to manage and elaborate the massive amount of collected datasets and to accu-
rately predict the treatment efficacy, the clinical outcome and the disease recurrence. Prediction of the treatment response can help in find-
ing an ad hoc adaptation for the best prognosis and outcome. Nowadays, personalised medicine requires an integrated interpretation of the 
results obtained by multiple diagnostic approaches, and biomedical images are crucial to provide real-time monitoring of disease progression, 
being strictly correlated to cancer molecular characterisation.
Radiomics is intended as the high throughput quantification of tumour properties obtained from the analysis of medical images [14, 15, 231]. 
Pathomics, on the other side, relies on generation and characterisation of high-resolution tissue images [16, 232, 233]. Many studies are 
focusing on the development of new techniques for image analysis in order to extrapolate information by quantification and disease char-
acterisation [234, 235]. Flexible databases are required to manage big volumes of data coming from gene expression, histology, 3D tissue 
reconstruction (MRI) and metabolic features (positron emission tomography, PET) in order to identify disease phenotypes [236, 237].
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Currently, there is an urgent need to define univocal data acquisition guidelines. Some initiatives to establish standardised procedures and 
facilitate clinical translation have been already undertaken, such as quantitative imaging network [238] or the German National Cohort 
Consortium [239]. Precise description of the parameters required for image acquisition and for the creation and use of computational and 
statistical methods are necessary to set robust protocols for the generation of models in radiation therapy. According to the US National 
Library of Medicine, approximately 50 clinical trials involving radiomics are currently recruiting patients, and a few have already been 
completed [240].
Conclusions and future perspectives
In recent years, research into cancer medicine has taken remarkable steps towards more effective, precise and less invasive cancer treat-
ments (Figure 1). While nanomedicine, combined with targeted therapy, helped improving the biodistribution of new or already tested 
chemotherapeutic agents around the specific tissue to be treated, other strategies, such as gene therapy, siRNAs delivery, immunotherapy 
and antioxidant molecules, offer new possibilities to cancer patients. On the other hand, thermal ablation and magnetic hyperthermia are 
promising alternatives to tumour resection. Finally, radiomics and pathomics approaches help the management of big data sets from cancer 
patients to improve prognosis and outcome.
At the moment, the most frequent entries concerning cancer therapies in the database of clinical trials (www.clinicaltrials.gov) involve the terms 
targeted therapy, immunotherapy and gene therapy, highlighting that these are the most popular methodologies under investigation, especially 
because, as already mentioned before, they have been shown to be very promising and effective (Figure 2A). However, Figure 2B shows that the 
clinical trials started in the past decade on different therapies mentioned in this review (except for liposomes-based therapies) have increased 
in number, showing how the interest on these new approaches is quickly growing in order to replace and/or improve conventional therapies. In 
particular, radiomics, immunotherapy and exosomes are the entries whose number has increased the most in the last 10 years.
Figure 1. Cancer therapy approaches: The image represents the most innovative strategies to treat cancer, combining different disciplines to obtain the 
most efficient and personalised therapy for patients.
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The current scenario for cancer research is wide, offering many possibilities for the constant improvement of treatment, considering not only 
patient recovery but also caring for their well-being during therapy. As summarised in Table 1, these new approaches offer many advantages 
compared to conventional therapies. However, some disadvantages still have to be overcome to improve their performances. Much progress 
has been made, but many others are likely to come in the near future, producing more and more ad hoc personalised therapies.
Figure 2. Cancer clinical trials. (A): Total number of clinical trials currently registered on www.clinicaltrials.gov for each approach discussed in this review. 
(B): Number of the clinical trials [in % respect with the total studies shown in (A)] started during the years 2008–2010 (blue) and from 2017 until today 
(orange). Date accessed: 01/08/19
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Table 1. Advantages and disadvantages of the main innovative cancer therapeutic approaches.
Strategy Advantages Disadvantages
Nanoparticles • High stability and specificity
• Good biocompatibility and bioavailability
• It depends on the particular nanoparticle
EVs • Physiologically secreted
• Good molecular characterisation
• High biocompatibility
• In vitro modifiable/loadable
•  Lack of preclinical procedures for isolation, quantification, 
storage and drug loading
Natural antioxidants • Easily available in large quantities
• Exploitation of their intrinsic properties
• Limited bioavailability
• Possible toxicity
Targeted therapy • High specificity
• Reduction of adverse reactions
• Lack of information regarding long-term side effects
Gene therapy • Expression of pro-apoptotic and chemo-sensitising genes
• Expression of wild type tumour suppressor genes
•  Expression of genes able to solicit specific anti-tumour 
immune responses
• Targeted silencing of oncogenes and safety (RNAi)
• Genome integration
• Limited efficacy in specific subsets of patients
• High chances to be neutralised by immune system
• Off-target effects and inflammation (RNAi)
• Need of ad hoc delivery systems (RNAi)
•  Set-up of doses and suitable conditions for controlled release 
(RNAi)
Thermal ablation
Magnetic hyperthermia
• Precise treatment of the interested area
•  Possibility to perform the treatment along with MRI imaging 
(magnetic hyperthermia)
• High efficiency only for localised areas
• Low penetration power
• Need for a skilled operator to perform the treatment
Radiomics/pathomics •  Creation of tumour whole tridimensional volume by non-
invasive imaging techniques
• Therapeutic and prognostic indicators of disease outcome
• Definition of univocal data acquisition guidelines
• Standardisation of procedures to facilitate clinical translation
•  Description of parameters and computational/statistical 
methods to set robust protocols for the generation of models 
for therapy
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